Filing Flows › Zymeworks (ZYME) › Stock forecast & fair value
Zymeworks (ZYME) stock forecast and fair value
Zymeworks (ZYME) trades at $25.79. 14 analysts' median price target is $38.50 (+49%), from $32.00 to $60.00. Across 11 valuation methods the middle fair value is $3.92 (-85%).
Fair value by method
| Method | Low | Point | High | vs price |
|---|---|---|---|---|
| EV/Sales vs peers | $3.62 | $4.45 | $6.30 | -83% |
| EV/Sales vs peers, weighted | $4.12 | $5.24 | $6.85 | -80% |
| EV/Sales vs peers, growth & margin adjusted | $3.31 | $3.92 | $4.96 | -85% |
| Residual income | −$0.97 | −$0.98 | −$1.00 | -104% |
| Analysts' price targets | $32.00 | $41.50 | $60.00 | +61% |
| Shareholder yield (dividends + buybacks) | $7.37 | $8.43 | $9.85 | -67% |
| Tangible book (asset value) | $0.75 | $0.94 | $0.94 | -96% |
| Survival-weighted value | $2.52 | $3.03 | $4.18 | -88% |
| Stage-weighted value (decline / turnaround) | $2.18 | $2.66 | $3.59 | -90% |
| Combined forecast (3 months) | $21.12 | $26.82 | $33.23 | +4% |
Zymeworks' latest quarter
Zymeworks, Q2 2026: revenue $4.6M (-91% year over year), operating margin -919.0%, net loss $45.0M, operating cash flow −$31.9M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for ZYME stock?
The median of 14 analysts' 12-month targets is $38.50, +49% from $25.79; the range is $32.00 to $60.00. The average rating is strong buy.
What is Zymeworks' fair value?
The fair-value methods on Filing Flows (DCF, Monte Carlo, peer multiples and others) put it between −$0.98 and $41.50, with a middle value of $3.92 against a price of $25.79. Each method's assumptions are on the page.
Does Zymeworks usually beat earnings estimates?
It beat the consensus EPS estimate in 25% of the quarters on record.
Is ZYME stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.